Business Context and Reporting Period
Company: Kewaunee Scientific Corporation
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Three and six months ended October 31, 2004
Business Overview: The Company manufactures laboratory furniture and fume hoods, serving pharmaceutical, educational, and industrial markets. Operations include domestic facilities and subsidiaries in Singapore and India.
Key Financial Metrics
| Metric ($ in thousands) | 3 Months Ended Oct 31, 2004 | 6 Months Ended Oct 31, 2004 | 3 Months Ended Oct 31, 2003 | 6 Months Ended Oct 31, 2003 |
|---|---|---|---|---|
| Net Sales | $18,365 | $38,653 | $24,384 | $48,597 |
| Gross Profit | $3,553 | $6,929 | $4,104 | $7,707 |
| Gross Margin % | 19.3% | 17.9% | 16.8% | 15.9% |
| Operating Earnings | $293 | $623 | $783 | $1,385 |
| Net Earnings | $108 | $301 | $418 | $879 |
| Diluted EPS | $0.04 | $0.12 | $0.17 | $0.35 |
| Cash from Operations (6mo) | $1,879 | ($2,186) | ||
| Working Capital | $13.9 million (Oct 31, 2004) | $12.6 million (Apr 30, 2004) | ||
| Short-term Borrowings | $6,079 | $6,996 (Apr 30, 2004) |
Material Changes vs. Prior Period
- Revenue Decline: Net sales decreased 24.7% for the quarter and 20.5% for the six-month period compared to the prior year. This was driven by delays in pharmaceutical research projects due to election uncertainty and reduced state funding for education construction.
- Margin Improvement: Despite revenue declines, gross profit margins improved (19.3% vs. 16.8% for the quarter) due to manufacturing efficiencies, partially offset by higher raw material (steel) and energy costs.
- Profitability Drop: Operating earnings fell significantly ($293k vs. $783k for the quarter) as operating expenses remained relatively flat while sales volume dropped, increasing the expense-to-sales ratio.
- Workforce Reduction: The Company reduced its Statesville workforce by approximately 18% (100 employees) to cut costs, with estimated annual savings of $3.6 million.
- Cash Flow Turnaround: Operating cash flow turned positive ($1.879 million) for the six months ended Oct 31, 2004, compared to a negative $2.186 million in the prior year, primarily due to a decrease in accounts receivable.
Outlook, Risks, and Management Commentary
- Market Risks: Continued uncertainty regarding the presidential election and prescription drug pricing is delaying pharmaceutical investments. High construction material costs (steel) are forcing customers to reduce project scopes.
- Backlog: Order backlog stood at $38.6 million as of October 31, 2004, down from $46.3 million in the prior year.
- Outlook: Management does not expect sales to improve until the fourth quarter, pending the resolution of election-related uncertainties.
- Liquidity: The Company maintains a revolving credit facility with $2.921 million available. Management believes current liquidity sources are sufficient to support operations and capital expenditures through the fiscal year.
- Unusual Items: Prior year "Other income" included a $295,000 gain from the resolution of a disputed claim, which is not present in the current period.
Investor Verification Checklist
- Verify the sustainability of the improved gross margins given rising steel and energy costs.
- Monitor the order backlog trend to confirm if the anticipated Q4 sales recovery materializes.
- Review the impact of the 18% workforce reduction on production capacity and future cost structures.
- Assess the Company's reliance on short-term borrowings ($6.1 million) and the status of the revolving credit line extension to December 2006.
- Confirm the timeline for the resolution of election-related uncertainties affecting pharmaceutical and education construction budgets.